Although plasma FGF21 levels have been described as biomarkers of metabolic disorders or mitochondrial myopathies (67–69), its release from muscle has been associated with improvements in metabolic function (42, 70, 71). This evidence concerns the gene FGF21 and Other metabolic disease.